

























































Towards Zwitterionic Oligonucleotides with Improved
Properties: the NAA/LNA-Gapmer Approach
Melissa Wojtyniak,[a] Boris Schmidtgall,[b] Philine Kirsch,[a] and Christian Ducho*[a, b]
In memory of Professor Thomas C. Bruice (1925–2019).
Oligonucleotides (ON) are promising therapeutic candidates, for
instance by blocking endogenous mRNA (antisense mecha-
nism). However, ON usually require structural modifications of
the native nucleic acid backbone to ensure satisfying pharma-
cokinetic properties. One such strategy to design novel
antisense oligonucleotides is to replace native phosphate
diester units by positively charged artificial linkages, thus
leading to (partially) zwitterionic backbone structures. Herein,
we report a “gapmer” architecture comprised of one zwitter-
ionic central segment (“gap”) containing nucleosyl amino acid
(NAA) modifications and two outer segments of locked nucleic
acid (LNA). This NAA/LNA-gapmer approach furnished a parti-
ally zwitterionic ON with optimised properties: i) the formation
of stable ON-RNA duplexes with base-pairing fidelity and
superior target selectivity at 37 °C; and ii) excellent stability in
complex biological media. Overall, the NAA/LNA-gapmer ap-
proach is thus established as a strategy to design partially
zwitterionic ON for the future development of novel antisense
agents.
Introduction
Oligonucleotides (ON) represent attractive candidates for novel
therapeutic agents due to their unique binding mode, that is,
hybridisation with complementary endogenous nucleic acids.
Hence, they enable interference with protein biosynthesis
through several modes of action: i) the antisense mechanism;[1]
ii) the antigene mechanism;[2] and iii) the RNA interference
mechanism.[3] These unique interaction pathways have already
been proven to be clinically useful. For instance, fomivirsen, an
antiviral antisense oligonucleotide used against cytomegalovi-
rus retinitis, was approved by the FDA as the very first antisense
drug on the market in 1998.[4a] In the following years, a few
other ON were approved for clinical use, such as mipomersen
for the treatment of familial hypercholesterolemia,[4b] nusinersen
against spinal muscular atrophy[4c] and eteplirsen to treat
Duchenne muscular dystrophy.[4d] However, the development of
ON into pharmaceuticals is significantly hampered due to
several characteristics of their phosphate diester backbone.
First, its dense negative charge results in restrained cell
permeability. Second, the native phosphate diester linkage is
labile towards nuclease-mediated hydrolysis.
In order to overcome these hurdles, a large toolbox of
various backbone modifications has been established over the
past decades. According artificial backbone structures can be:
i) the sole substitution of single atoms within the phosphate
diester unit, for example, methylphosphonates[5] or the broadly
used phosphorothioates;[6] ii) replacement of the phosphate
diester with electroneutral groups, for instance with amides[7] or
sulfones;[8] iii) a complete replacement of the native sugar-
phosphate backbone, such as in peptide nucleic acids (PNA).[9]
Furthermore, modifications of the (2’-deoxy)ribose units can
also furnish improved properties of ON analogues. For instance,
Wengel and co-workers have developed unnatural locked
nucleic acids (LNA) to alter the native ON characteristics
(Figure 1A).[10] The LNA modification is characterised by an
additional bridging bond, linking the 2’-oxygen of the ribose
with the 4’-position, thus locking it in the 3’-endo conformation.
Insertion of this rigid sugar significantly increases binding
affinity towards RNA, due to a reduced entropic penalty upon
hybridisation. In addition, the LNA modification was shown to
significantly enhance stability against nuclease-mediated degra-
dation, thereby improving the overall stability in biological
media. As a result, LNA-modified ON have found pronounced
attention as potential biomedical agents.[10c] Yet, the improved
affinity for duplex formation was also shown to be accompa-
nied by limited sensitivity towards base mismatches and thus,
by decreased binding selectivity. Furthermore, the high melting
temperatures of LNA-ON in complex with their RNA targets
have been shown to be correlated to increased cytotoxicity
resulting from elevated off-target effects, as well as increased
hepatotoxic risks.[11a] To elucidate this toxic potential, Die-
ckmann et al. have developed an in vitro approach to evaluate
the hybridisation-dependent toxicity of high-affinity ON, which
confirmed a correlation of high melting temperatures (Tm
values) and undesired toxic effects.[11b]
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An alternative strategy in the development of backbone-
modified ON involves the replacement of the anionic
phosphate diester unit with artificial, positively charged linkers,
thus creating an either partially zwitterionic[12] or fully cationic[13]
ON. This approach significantly differs from the introduction of
positive charges by modification of the 2’-hydroxy groups (in
RNA) or nucleobases, while leaving the phosphate diester
backbone unchanged. Such strategies also afford zwitterionic
structures, but result in densely charged oligonucleotides.[14] In
contrast, cationic replacements of the anionic phosphate diester
enable the synthesis of artificial ON with a reduced net charge
due to the compensation for adjacent phosphates. This
substitution has been shown to have a positive effect on the
ability to penetrate biological barriers such as cellular
membranes.[15] So far, four suitable types of unnatural cationic
linkers have been reported: i) Letsinger’s phosphoramidate
linkages[16] that carry a positively charged head group con-
nected to the phosphate by an alkyl chain; ii) the guanidine[17]
and iii) S-methylthiourea[18] modifications, both first described
by Bruice et al.; and the iv) nucleosyl amino acid (NAA)
modification (Figure 1A), an amide-derived cationic backbone
motif previously reported by our group.[12,13b,c,19]
The NAA internucleoside structure has been formally
derived from the “high-carbon” nucleoside core unit of naturally
occurring muraymycin antibiotics and their synthetic
analogues.[12,20] In terms of conformational flexibility, the NAA-
linkage is somewhat intermediate to the rather flexible
phosphoramidates and the rigid guanidines and S-meth-
ylthioureas. Its peptide-like structure features a primary amino
group carrying a positive charge at physiological pH. This unit
can be attached with a specific spatial orientation, that is, with
stereoselectivity at the 6’-position of the adjacent “high-carbon”
nucleoside.[12,13b,c] Partially zwitterionic ON including up to four
NAA-modifications in an otherwise anionic (i. e., phosphate-
based) backbone had previously been proven to form stable
helical duplexes with complementary DNA. They were also
shown to preserve excellent base-pairing fidelity, as demon-
strated by decreasing melting temperatures due to base
mismatches in the DNA counterstrand. For hybrid duplexes of
NAA-containing DNA-ON with RNA, however, a fairly significant
loss in thermal stability was observed (ΔTm up to ~4.0 °C/
modification). In this context, the 6’S-configured NAA linkage
seemed to exert a slightly greater destabilising effect than the
6’R-configured congener.[12a] The biological in vitro evaluation of
NAA-modified DNA-ON confirmed high stability against cleav-
age by 3’!5’- and 5’!3’-exonucleases as well as in more
complex biological media (human plasma, whole cell lysate).[19]
For the future development of NAA-containing partially
zwitterionic ON towards potential biomedical agents, one major
issue was the undesired decrease in thermal stability for
duplexes with complementary RNA strands (as these would
represent the drug targets in antisense applications). Hence, we
have envisioned to overcome this hurdle by using a “gapmer”
approach,[21] that is, a hybrid structure with different internu-
cleoside linkages in the middle of the ON than at its ends. The
overall goal was to obtain a chimeric, partially zwitterionic NAA-
containing ON that exerts high affinity towards its target RNA,
while still showing excellent base-pairing fidelity. LNA units
facilitate the formation of thermally highly stable DNA/RNA
heteroduplexes (vide supra). Hence, it was planned to exploit
this feature for the design of according NAA-containing
gapmers. We have therefore designed a partially zwitterionic
gapmer-ON consisting of LNA segments at the 3’- and the 5’-
ends and a block of 6’R-configured NAA-modified DNA filling
the “gap” in the central section (Figure 1A).
In this work, we report the synthesis of the novel NAA/LNA-
gapmer 1 (with a partially zwitterionic backbone) and its
properties in comparison with DNA/LNA-gapmer 2 (as a
reference ON with a fully anionic backbone, Figure 1B). The
identical base sequence of 1 and 2 has been artificially
designed in order to study the fundamental principles of a
zwitterionic gapmer construct such as 1, that is, its sequence is
not (yet) designed to target a specific biologically relevant RNA
sequence. The choice of this sequence was based on synthetic
considerations and the goal to obtain an ON containing all four
canonical bases, while having a reasonable G-C content. The
reported results strongly indicate that the NAA/LNA-gapmer
approach is a useful strategy to design partially zwitterionic ON
with improved properties.
Results
Synthesis of gapmer ON 1and 2
It was envisioned to prepare both target ON 1 and 2 (Figure 1)
by modified automated solid-phase-supported ON synthesis
using phosphoramidite methodology. To synthesise the NAA/
LNA-gapmer 1, a “dimeric” CxT  NAA phosphoramidite (with
Figure 1. A) Schematic representation of the NAA/LNA-gapmer approach.
B=nucleobase, L=LNA-modification, x=NAA-modification. B) Sequences of
novel NAA/LNA-gapmer 1 and DNA/LNA-gapmer 2 (as reference ON). All
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6’R-configuration in the NAA linkage) had to be prepared.[12]
Thus, the aforementioned goal to obtain a gapmer ON with
reasonable G-C content could be reached, as the only
previously reported “dimeric” NAA phosphoramidites had been
TxT[12a] and AxT,[12b] respectively (with “x” representing the NAA
linkage, cf. Figure 1). The synthesis of this novel CxT-NAA
phosphoramidite required the preparation of a suitably pro-
tected 3’-amino-2’,3’-dideoxycytidine building block (Scheme 1).
Different synthetic routes towards such a 3’-aminodeoxycyti-
dine building block had been described before.[22] With respect
to its elegance and high stereoselectivity, our synthetic strategy
was mainly based on the procedure reported by Richert and co-
workers.[22d]
Thus, 2’-deoxycytidine 3 was N-benzoylated at the nucleo-
base using a standard transient protection protocol,[23] furnish-
ing N-benzoyl-2’-deoxycytidine 4 in 96% yield (Scheme 1). In
contrast to the recrystallisation procedure described by Ti et al.,
compound 4 was purified by column chromatography to
remove excess benzoic acid. This was followed by a sequence
of two Mitsunobu reactions, with the first one leading to 5’-(p-
bromobenzoyl) protection and the second one enabling ring
closure of the cytosin-2-O and C-3’, to give cyclised product 5 in
39% yield. Nucleophilic substitution (SN2) at C-3’ with sodium
azide then furnished 3’-azidonucleoside 6 in 66% yield. After
saponification of the p-bromobenzoyl ester, silylation gave 5’-O-
TBDMS-protected derivative 7 in 85% yield over two steps from
6. Finally, reduction of the azido group by transfer
hydrogenation[24] afforded the desired protected 3’-amino-2’,3’-
dideoxycytidine derivative 8 in 96% yield (Scheme 1).
Based on our stereoselective route for the synthesis of
uridine-derived nucleosyl amino acids,[25] we had previously
developed the preparation of according thymidine
derivatives.[12,13b] Hence, this reported protocol was used to
prepare protected nucleosyl amino acid 9 (Scheme 2, reactions
not shown).[12] Thymidine derivative 9 underwent amide
coupling with 3’-aminonucleoside 8 to furnish the bis-silylated
NAA-linked C-T dimer 10 in 78% yield. Fluoride-mediated
desilylation gave diol 11 in a moderate yield of 53%. Attempts
to improve this deprotection protocol for the TBDMS ethers
were not successful, as changes in the reaction conditions
always led to more side reactions or even complete decom-
position of starting material 10. Regioselective 5’-O-dimeth-
oxytritylation afforded 5’-O-DMTr-protected NAA-linked dimer
12 (64% yield), which was then phosphitylated (using diamidite
reagent 13) to give the dimeric NAA-linked C-T phosphorami-
dite 14 in 78% yield (Scheme 2).
With the NAA-linked C-T phosphoramidite 14 in hand, both
gapmers 1 and 2 (Figure 1) were assembled on the DNA
synthesiser. Standard protocols were slightly adjusted (see the
Supporting Information for details). In general, coupling times
for LNA and NAA phosphoramidites were prolonged relative to
their commercially available, unmodified DNA congeners, and
the number of couplings was increased to enhance the step-to-
step yield. With respect to the activator for phosphoramidite
coupling, it was found that benzylmercaptotetrazole (BMT) was
superior to 4,5-dicyanoimidazole (DCI) as it gave higher yields,
in particular when the NAA-linked building block 14 was
coupled. Apart from this, standard solvents and reagents for
solid-phase-supported DNA synthesis and the usual basic work-
up procedure were used. Purification of gapmers 1 and 2 was
achieved by polyacrylamide gel electrophoresis (PAGE) with
urea as chaotropic component. The identities of gapmers ON 1
and 2 were confirmed by high resolution mass spectrometry
(see the Supporting Information).
NAA/LNA-gapmer 1shows superior hybridisation properties
at physiologically relevant temperature
One main goal of the reported gapmer approach was to
enhance the stability of NAA-containing DNA-RNA hybrid
duplexes, while retaining base-pairing fidelity. Therefore, melt-
ing temperature experiments with fully complementary strands
as well as with mismatched RNA-ON X (base mismatch opposite
of one of the LNA segments: 5’-AAUCUAGAGAGAGACCU-3’)
and mismatched RNA-ON Y (base mismatch opposite of the
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central NAA gap: 5’-AAUCUAGAGGGAGAUCU-3’) were per-
formed. To eliminate the temperature dependency of the
extinction coefficient ɛ, αTm values were calculated and used to
describe the melting temperature of all studied duplexes.
Furthermore, αT37°C values were calculated to investigate the
hybridisation at a physiologically relevant temperature of 37 °C
(for more details see the Supporting Information). The obtained
results are given in Table 1, with selected melting curves shown
in Figure 2.
Satisfactorily, the duplex stability of the NAA/LNA-gapmer 1
(Figure 1) with fully complementary DNA was equal to the
according native DNA/DNA duplex (αTm=48.5 °C, entries 9 vs. 1,
Table 1), whereas control gapmer 2 furnished an even higher
value (ΔαTm= +4.5 °C, entry 5). This was also the case for the
2-RNA duplex, for which an even stronger increase in melting
temperature was observed (ΔαTm= +17.0 °C, entry 6). This was
anticipated as the LNA segments in gapmer 2 were supposed
to stabilise duplexes with native RNA.[10] However, for the
hybridisation of the complementary RNA strand with NAA-
Scheme 2. Synthesis of the “dimeric” NAA-linked C  T phosphoramidite 14 for automated ON synthesis.
Table 1. αTm values [°C] of native DNA (entries 1–4), DNA/LNA-gapmer 2 (entries 5–8) and NAA/LNA-gapmer 1 (entries 9–12) in complex with either
complementary DNA, complementary RNA, mismatched RNA X, and mismatched RNA Y, respectively. L=LNA modification, x=NAA modification (Figure 1).
All unlabelled linkages are native phosphate diesters. Mismatches in RNA-ON X and Y are highlighted in bold and underlined.






1 DNA+DNA 48.5 – 0.97 97 3
2 DNA+RNA 55.5 – 1.00 100 0
3 DNA+X 50.0 – 0.97 97 3
4 DNA+Y 52.0 – 0.98 98 2
5 gapmer 2+DNA 53.0 4.5 0.98 98 2
6 gapmer 2+RNA 72.5 17.0 1.00 100 0
7 gapmer 2+X 62.5 12.5 1.00 100 0
8 gapmer 2+Y 68.5 16.5 1.01 100 0
9 gapmer 1+DNA 48.5 0.0 0.96 96 4
10 gapmer 1+RNA 49.5   6.0 0.98 98 2
11 gapmer 1+X 37.0   13.0 0.51 51 49
12 gapmer 1+Y 43.0   9.0 0.86 86 14
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containing gapmer 1, this overall stabilising effect was not
found. Instead, a slight decrease in the melting temperature
was observed (ΔαTm=   6.0 °C, entry 10). This decrease in
duplex stability is equivalent to about   5.8 °C per NAA
modification (entry 10 vs. entry 6), which is similar to the
previously described destabilising effect of the NAA modifica-
tion on DNA-RNA hybrid duplexes (~3.5 °C per NAA modifica-
tion for a comparable type of sequence).[12a] The presence of the
stabilising LNA units then limits the overall destabilisation of
the 1-RNA duplex to a formal value of   1.5 °C per NAA
modification (entry 10 vs. entry 2). Therefore, the results
obtained with ON 1 demonstrated that the gapmer architecture
with two flanking LNA segments indeed furnished an improved
duplex stability for hybridisation with RNA.
For a more detailed analysis of the hybridisation properties
of gapmer 1, we considered the overall ratio of hybrid duplex
to free single strands at physiological human body temperature
(37 °C), as this property is decisive for any potential in vivo
application of antisense ON. Thus, the y values of the α-curve
for T=37 °C were determined for every thermal denaturation
experiment (αT37°C values, Table 1, see also the Supporting
Information for the exact procedure). These values correspond
to the amount of duplex present at this given temperature and
can therefore also be expressed as a percentage of hybridised
(i. e., bound) ON (αT37°C values in %). Correspondingly, the term
1  αT37°C provides the unbound, single-stranded ON fraction
(Table 1). It was found that hybridisation of native DNA and
RNA of the given sequence occurred with 100% at 37 °C
(entry 2, Table 1). This was also the case for the mixture of
reference gapmer 2 and complementary RNA under these
conditions (entry 6). For the NAA/LNA-gapmer 1 and comple-
mentary RNA, almost quantitative (98%) hybridisation at 37 °C
was determined, with only ~2% single-stranded fraction
(entry 10). This demonstrated the possibility to achieve excel-
lent target engagement by such an NAA-containing gapmer
under physiologically relevant conditions.
We then studied the base-pairing fidelity of NAA/LNA-
gapmer 1, that is, its hybridisation properties with RNA-ON
containing a single base mismatch. Therefore, gapmer 1 as well
as both reference ON (2 and native DNA, respectively) were
investigated for duplex formation with two different mis-
matched RNA-ON: i) the aforementioned RNA strand X having a
mismatching base opposite one of the LNA segments of 1; ii)
the aforementioned RNA strand Y having the mismatch
opposite the zwitterionic NAA-modified gap of 1. In all resultant
cases (i. e., with gapmers 1 and 2 as well as with native DNA), a
decrease in thermal duplex stability due to the introduction of
base mismatches was observed (entries 3 and 4 vs. entry 2;
entries 7 and 8 vs. entry 6; entries 11 and 12 vs. entry 10,
Table 1; also see Figure S7 in the Supporting Information).
Furthermore, in all of these experiments, the mismatch-
mediated destabilisation of duplex structures was most pro-
nounced when the mismatched base was placed opposite the
LNA segment, that is, with RNA-ON X as counterstrand
(entries 3, 7, and 11). Interestingly, NAA/LNA-gapmer 1 proved
to be highly sensitive towards both mismatched RNA-ON X and
Y (entries 11 and 12 vs. entry 10). In this case, mismatch
recognition was found to be even better than for the native
DNA strand (entries 3 and 4 vs. entry 2), as expressed by a
stronger mismatch-induced destabilisation of the duplex struc-
tures. Again, the duplex-to-single strand ratio at 37 °C was
determined from the melting curve data (vide supra). Both
reference ON (gapmer 2 and native DNA) showed a large
percentage of duplex structures at 37 °C (αT37°C=97–100%),
both with X and Y as counterstrands (entries 3, 4, 7, and 8).
Only the NAA/LNA-gapmer 1 was partially dissociated from the
mismatched RNA-ON under these conditions (entries 11 and
12). In the presence of Y, 14% of gapmer 1 was not bound to
the RNA-ON, and with X, the unbound fraction of the gapmer
was even ~50%. This selectivity in RNA binding led to the
conclusion that the hybridisation properties of NAA/LNA-
gapmer 1 are superior relative to both the reference gapmer 2
and to native DNA (vide infra), even though the presence of the
NAA-modification furnished a moderate decrease of thermal
duplex stability.
Circular dichroism spectra of both gapmers in complex with
DNA or RNA demonstrate structural resemblance to a
DNA-RNA heteroduplex
In order to elucidate the structural properties of the partially
zwitterionic NAA/LNA-gapmer 1, circular dichroism (CD) spectra
of duplexes of 1 either with complementary DNA (Figure 3A) or
RNA (Figure 3B) were recorded and compared to the respective
Figure 2. A) Melting curves of native DNA, DNA/LNA-gapmer 2, and NAA/
LNA-gapmer 1 in complex with complementary DNA. B) Melting curves of
native DNA, DNA/LNA-gapmer 2, and NAA/LNA-gapmer 1 in complex with
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spectra of DNA/LNA-gapmer 2 with complementary counter-
strands.
For the duplexes of either gapmers 1 or 2 with DNA, CD
signals indicated more resemblance between both gapmer-
containing duplexes than to the unmodified DNA–DNA duplex
of the same sequence (Figure 3A). In particular regarding the
distinct negative signal at 210 nm and the following positive
amplitude at 225 nm – which were almost nonexistent for the
DNA-DNA reference duplex – duplexes containing gapmers 1
and 2 showed pronounced similarities. This hints towards
substantial structural differences in the conformation of both
gapmer-DNA duplexes as compared to the native DNA-DNA
helix. However, when according duplexes with a complemen-
tary RNA counterstrand were studied, striking similarities to the
unmodified DNA-RNA congener were observed (Figure 3B). In
this case, the CD signals of the 1-RNA duplex almost perfectly
superposed with the native DNA-RNA duplex. This was also the
case for reference gapmer 2, with the slight difference that the
negative signal at 210 nm was stronger than for the other two
duplexes. Furthermore, the CD spectra of the 1-RNA and 2-RNA
duplexes show some resemblance to the spectra of the 1-DNA
and 2-DNA congeners, respectively (Figure 3B vs. A). Overall,
these results therefore demonstrate that both gapmers 1 and 2,
either in complex with DNA or RNA, furnish duplexes with
topologies similar to a DNA-RNA heteroduplex. Remarkably, this
finding was independent of the charge pattern in the ON
backbone, that is, the partially zwitterionic nature of gapmer 1.
Both gapmer ON show excellent stability in biological media
Stability in biological media is crucial for any potential in vivo
application of antisense ON. Therefore, we tested the stability
of both gapmers 1 and 2 in pooled human plasma (HP;
Figure 4A) as well as in whole cell lysate (WCL) of the human
U937 cell line (Figure 4B). Unmodified DNA served as the
positive (i. e., degradable) control in both assays.
We had previously reported that NAA-modified ON have
potentially excellent stabilities in such media, dependent on the
position of the cationic NAA-linkage.[19] LNA-modified ON are
also known to show an improved stability against nuclease-
mediated degradation[26a] and also in human serum, relative to
unmodified controls.[26b] In this work, we have aimed to verify
the thus anticipated stability of gapmers 1 and 2 in the
aforementioned biological media. Analysis by urea-PAGE dem-
onstrated that both gapmers 1 and 2 show excellent stability
against cleavage in HP (Figure 4A) as well as in WCL (Figure 4B)
over a time course of eight hours, whereas an unmodified DNA-
ON of the same sequence was completely cleaved.
Duplex formation of NAA/LNA-gapmer 1with complementary
RNA results in moderate activation of RNase H
In order to determine whether NAA/LNA-gapmer 1 is capable of
triggering RNase H-mediated cleavage of complementary RNA,
an assay employing a 5’-32P-labelled RNA strand was used.[27]
Duplexes of native DNA as well as of DNA/LNA-gapmer 2,
respectively, with this RNA strand served as controls, with the
Figure 3. CD spectra of native DNA, DNA/LNA-gapmer 2, and NAA/LNA-
gapmer 1 in complex with complementary A) DNA and B) RNA. All depicted
curves are the average of technical triplicates.
Figure 4. Effect of A) human plasma (HP) and B) human whole-cell lysate
(WCL) on native DNA as well as on gapmers 1 and 2, respectively, over a
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DNA-RNA heteroduplex representing a positive control, that is,
a system furnishing RNase H-catalysed RNA degradation.
Figure 5A shows the results of the incubation of the labelled
RNA with all three aforementioned strands, respectively, and
RNase H over a time course of 60 min. Furthermore, the bottom
panel depicts the influence of RNase H on the 32P-labelled RNA
strand without the presence of any counterstrand as an
additional control experiment. Analyses of the assay mixtures
were carried out by urea-PAGE and autoradiography. As
anticipated,[28] DNA/LNA-gapmer 2 induced the activation of
RNase H and led to complete degradation of the parent RNA
strand within the first 5 min of incubation (Figure 5A, degrada-
tion product label b). The timepoint of 0 min shows the intact
RNA (Figure 5A, label a) as well as a band of the 2-RNA duplex
(label x) which was still present despite the addition of urea as
chaotropic agent. Similar observations were made for unmodi-
fied DNA that likewise triggered rapid degradation after 5 min,
but led to the formation of an additional degradation product.
In contrast, single-stranded RNA without a complementary
counterstrand remained stable against RNase H over the
observed timeframe. Interestingly, NAA/LNA-gapmer 1 also
induced RNase H-mediated cleavage of the target RNA,
although no uniform phosphate diester backbone was present
in its structure. However, the rate of degradation appeared to
be significantly slower than for reference gapmer 2.
We therefore performed a second set of experiments to
observe RNase H-mediated degradation over an extended time
period (Figure 5B). After 24 h, degradation of the labelled RNA
was clearly detectable in the assay mixture containing NAA/
LNA-gapmer 1, yet nearly the exact same outcome was
observed without the presence of 1. To rule out general
instability of the chosen RNA sequence over such an extended
time period, another control experiment was included: 32P-
labelled RNA was incubated over the full time period (i. e., up to
24 h) in the absence of both a counterstrand and RNase H.
However, no RNA cleavage was detected under these con-
ditions (Figure 5B). It has to be noted that the degradation
signals observed for the duplex of 1 and 32P-labelled RNA after
30 and 60 min (Figure 5A) could not be visualised in the
prolonged incubation experiment (Figure 5B) due to differences
in signal intensity.
Discussion
In previous studies,[12a,19] we reported the generally favourable
properties of ON with partially zwitterionic NAA-modified back-
bone structures, that is, their formation of stable, helical
duplexes with complementary DNA, their retention of base-
pairing fidelity and their high stability in biological media.
However, duplex formation with RNA had been observed to be
moderately hampered, that is, decreased thermal stabilities (up
to   4.0 °C/NAA-modification[12a]) had been observed. Thus, we
have now aspired to modify such zwitterionic NAA-ON in a way
that furnishes satisfactory binding affinity towards RNA without
compromising base-pairing fidelity, hence potentially enabling
an efficient and selective target engagement with endogenous
RNA. These considerations have led to the design of NAA/LNA-
gapmer 1, in which strongly RNA-binding LNA segments were
combined with a zwitterionic NAA-modified gap unit.
Following the successful synthesis of 1 (and an according
DNA/LNA-gapmer 2 as a reference with a uniformly anionic
backbone), UV-monitored thermal melting studies revealed an
improved binding affinity to complementary RNA, relative to
previously studied NAA-modified ON (formally   1.5 °C/NAA-
modification due to the stabilising effect of the LNA units). As a
Figure 5. A) RNase H-mediated degradation of 32P-labelled RNA upon hybridisation with 1, 2, native DNA, and without any counterstrand over 60 min (urea-
PAGE). B) RNase H-mediated degradation of 32P-labelled RNA with 1, without any counterstrand, and without either counterstrand or RNase H over 24 h (urea-
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result, almost quantitative formation of the 1-RNA duplex at
physiologically relevant 37 °C could be demonstrated. Further-
more, gapmer 1 was shown to be sensitive towards single base
mismatches in the counterstrand at 37 °C. Experiments with
mismatched RNA X resulted in only 50% formation of the 1-
RNA duplex at this temperature. With a different mismatched
RNA Y, 14% single-stranded gapmer 1 was determined (cf.
Table 1). Interestingly, this selectivity was not observed with the
DNA/LNA-gapmer 2 (i. e., the polyanionic reference ON) that
showed no sensitivity towards base mismatches in the RNA
counterstrand at 37 °C. The same was true for unmodified DNA.
Binding to RNA off-targets with sequences similar to the actual
target mRNA can lead to potential side effects in the
pharmaceutical application of antisense ON.[29] It is therefore of
great relevance that backbone-modified ON structures show
some sequence selectivity in their hybridisation properties
under physiologically relevant conditions (i. e., at 37 °C). With
respect to this consideration, the hybridisation properties of
NAA/LNA-gapmer 1 are superior relative to those of both the
reference gapmer 2 and native DNA, even though the presence
of the NAA-modification furnished a decrease of thermal duplex
stability. Furthermore, these results give rise to the general
question if Tm values might be overrated in the evaluation of
hybridisation properties of backbone-modified ON with respect
to their potential application as antisense agents. We present
herein an alternative parameter for such an evaluation: the
target selectivity of the investigated ON (with a suitable length
for an antisense agent) at 37 °C. This appears to be superior to a
“the more stable, the better” approach for studying the
physicochemical hybridisation properties with RNA counter-
strands. This hypothesis is also supported by recent findings by
Dieckmann et al. who could demonstrate a direct correlation of
high Tm values and the hepatotoxic potential of high-affinity ON
due to enhanced off-target effects.[11b] Of course, such an
improved target selectivity due to decreased duplex stability
can in principle also be achieved by alternative means, for
example, designing a shorter sequence of the antisense ON or a
lower number of LNA units. However, herein we demonstrate
that the NAA-modification is a useful addition to the toolbox of
ON modifications to achieve this goal.
CD-spectroscopic analyses confirmed helical topologies for
the gapmers 1 and 2, respectively, in complex with comple-
mentary DNA or RNA, with the resultant helical structures being
similar to a DNA-RNA heteroduplex in all cases. This uniform
topological preference was obviously caused by the presence of
the LNA segments in the gapmer sequences.[30] Notably, the
partially zwitterionic backbone structure of 1 had no distorting
influence on the topologies of its duplexes formed with either
DNA or RNA counterstrands. In addition, high stability against
degradation of the gapmers in human plasma and whole cell
lysate was observed.
The activation of RNase H generally represents a desirable
(though not essential feature) of antisense ON, and the NAA/
LNA-gapmer 1 was therefore investigated with respect to this
property. In a first set of experiments, the RNase H-mediated
cleavage of a complementary 32P-labelled RNA counterstrand
was studied over a period of 60 min. Within this time, the two
reference ON (i. e., gapmer 2 and unmodified DNA) both
induced rapid degradation of the target RNA by RNase H.
Surprisingly, some degradation of the labelled RNA (albeit
rather slowly) was also detected in presence of NAA/LNA-
gapmer 1, although 1 possesses no uniform phosphate diester
backbone (cf. Figure 5). This suggested a very moderate
activation of RNase H due to the presence of 1 in the assay
mixture. In order to further study this effect, the assay was then
performed again with a significantly extended incubation
period (up to 24 h). Even though this led to stronger signals for
the RNA degradation products with gapmer 1, this result could
not solely be linked to the influence of the partially zwitterionic
gapmer: the same experimental setup with the absence of 1
resulted in a rather similar outcome. To exclude a general
instability of the radiolabelled RNA strand, an additional control
containing only the target RNA without RNase H was also
incubated for 24 h, but no degradation was recorded. This
demonstrated that the employed preparation of RNase H
displayed some sort of unspecific nuclease activity. Overall, it
was concluded that the aforementioned very moderate activa-
tion of RNase H by gapmer 1 became indistinguishable from
background reactions over longer incubation periods. This
suggests that an NAA/LNA-gapmer of type 1 might exert a
potential antisense effect by “steric block” (i. e., binding to
endogenous RNA) rather than by “catalytic” RNA degradation,
as the latter would probably require a more efficient activation
of RNase H. It should also be noted that this part of the
reported work generally proves the high relevance of a rigorous
set of control experiments in RNase H assays. Otherwise, it is
unclear if the described alleged activation of RNase H was
genuine or actually resulted (at least partially) from unspecific
nuclease activity. This actually might be the case for several
reports on ’RNAse H activation’ by modified ON structures in
the literature.
Conclusion
In summary, we report the synthesis and properties of a new
type of gapmer oligonucleotide architecture featuring a parti-
ally zwitterionic backbone structure. This NAA/LNA-gapmer
approach furnished a zwitterionic ON 1 with optimised
characteristics: gapmer 1 showed superior hybridisation proper-
ties with RNA at physiologically relevant 37 °C as well as
excellent stability in biological media. In a cellular setting, a
gapmer of type 1 might then mainly exert biological activity via
a ’steric block’ mechanism, even though 1 apparently activated
RNase H-mediated RNA degradation on a very moderate level.
Overall, the NAA/LNA-gapmer approach is thus established as a
strategy to design partially zwitterionic ON for the future
development of novel antisense agents with a reduced overall
charge in the backbone. This is anticipated to furnish improved
pharmacokinetic properties of according ON-based drug candi-
dates. Based on the favourable characteristics of 1, the stage is
now set for the development of synthetic methodology for the
efficient preparation of zwitterionic gapmers of type 1 with
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studies on their antisense efficacy in cellulo, with the goal to
establish zwitterionic backbone architectures of oligonucleotide
analogues as a viable strategy for the development of novel
antisense agents.
Experimental Section
Synthesis of oligonucleotides: Based on our previous syntheses of
NAA-modified ON,[12] gapmer ON 1 and 2 were assembled by
automated solid phase-supported DNA synthesis. This required the
chemical synthesis of “dimeric” NAA-linked phosphoramidite 14
(see the Supporting Information for detailed synthetic procedures).
Unmodified DNA phosphoramidites (Glen Research) and LNA
phosphoramidites (QIAGEN) were commercially purchased. After
completion of ON synthesis and basic workup under standard
conditions, purification of 1 and 2 was achieved by urea
polyacrylamide gel electrophoresis (urea-PAGE, Figure S1, see the
Supporting Information for detailed procedures). The identities of
both gapmers 1 and 2 were confirmed by high resolution mass
spectrometry (Table S1, Figures S2 and S3). All other oligonucleo-
tides were commercially purchased (Sigma-Aldrich).
Melting temperature experiments: To determine the binding
affinity of the NAA/LNA-gapmer 1 towards complementary DNA (5’-
AATCTAGAGAGAGATCT-3’) and RNA (5’-AAUCUAGAGAGAGAUCU-
3’), a 1 μM solution of the gapmer/counterstrand duplex in
phosphate buffer (10 mM NaH2PO4, pH 7.4, containing 100 mM
NaCl) was prepared. Prior to measurements, the solution was
heated to 90 °C and subsequently cooled down to RT to enable
duplex formation. Then, three heating and cooling cycles ranging
from 25 to 90 °C with a heating rate of 0.7 °C/min were performed
and changes in the absorption at λ=260 nm were recorded using a
Cary 100 UV/Vis spectrometer (Agilent Technologies). Hyperchro-
micity was plotted against temperature to obtain melting curves,
and Tm values were calculated as the maximum of the first
derivative. To eliminate the temperature dependency of the
extinction coefficient ɛ, αTm values were calculated and used to
describe the melting temperature of all studied duplexes. Further-
more, αT37°C values were calculated to investigate the hybridisation
at a physiologically relevant temperature of 37 °C. Details on the
method for the compilation of the α-curves are provided in the
Supporting Information (Figures S4 to S6). A similar protocol was
used for studies on mismatch sensitivity. Therefore, base mis-
matches were introduced in the RNA counterstrand opposite of
either one of the LNA segment (5’-AAUCUAGAGAGAGACCU-3’,
mismatched RNA-ON X) or the NAA gap (5’-AAUCUAGAGGGAGAU-
CU-3’, mismatched RNA-ON Y, mismatches are highlighted in bold
and are underlined in the sequences, also see Figure S7). To obtain
reference Tm values, according melting temperature experiments
were conducted with DNA/LNA-gapmer 2 and a native DNA-ON
with the same sequence (5’-AGATCTCTCTCTAGATT-3’).
CD-spectroscopic analysis of duplex structures: Circular dichroism
(CD) spectra of duplexes containing the NAA/LNA-gapmer 1 were
recorded in phosphate buffer (10 mM NaH2PO4, pH 7.4, containing
100 mM NaCl) on a Jasco 715 spectropolarimeter. The final
concentration of the duplex was 1 μM. All measurements were
performed at 25 °C in a cuvette with a length of 1 cm and a
wavelength range of 200–320 nm. Every sample was scanned
10 times with a scanning speed of 200 nm/min, a bandwidth of
5 nm, response time of 2 s and a data pitch of 0.5 nm. Prior to data
analysis, a background correction was performed. Spectra were
obtained by plotting the mean residual ellipticity Θ against the
recording wavelength λ. Reference spectra were recorded using the
same protocol and duplexes containing either the DNA/LNA-
gapmer 2 or a native DNA-ON with the same sequence (5’-
AGATCTCTCTCTAGATT-3’).
Stability assays in biological media: The stabilities of both gapmer
ON 1 and 2 in biological media was studied using pooled human
plasma and whole-cell lysate of the U937 cell line as described
before.[19] As a positive control for the degradation of ON in these
media, a native DNA-ON with the same sequence (5’-
AGATCTCTCTCTAGATT-3’) was used. In contrast to the previously
reported protocol,[19] incubation times for both ON were increased
to a total of 8 h. Samples were taken at the time points shown in
Figure 4 (vide supra). Pooled human plasma was obtained from
BIOTREND Chemikalien GmbH. U937 cells were purchased from
Sigma-Aldrich and the whole-cell lysate was prepared as
reported.[19]
RNase H assays: An RNA-ON with a sequence (5’-AAUCUAGAGAGA-
GAUCU-3’) complementary to the gapmer sequence was radio-
labelled at the 5’-end using γ-32P-ATP (Hartmann Analytics, 500 μCi).
The phosphorylation reaction was catalysed by T4 polynucleotide
kinase according to the manufacturer‘s protocol (kit for DNA/RNA
5’-end labelling, Thermo Scientific). The resultant 5’-radiolabelled
RNA was purified on an illustra NAP-5 gravity flow column (GE
Healthcare) using water (Milli-Q) as eluent. The solvent was
evaporated under reduced pressure and the dry 5’-32P-labelled RNA
was redissolved in water to a final concentration of 10 μM. The
labelled RNA (2.5 pmol) was then combined with the NAA/LNA-
gapmer 1 (5 pmol), diluted with 10x Reaction Buffer (Thermo
Scientific) to a total volume of 25 μL and incubated at 37 °C for
15 min to allow formation of the hybrid duplex. Subsequently,
RNase H from E. coli MRE-600 cells (Thermo Scientific, 1 μL, 10 U)
was added and the mixture was incubated at 37 °C. Samples were
taken at the time points shown in Figure 5 (vide supra) and the
reaction was quenched by addition of stop-mix (50 mM EDTA, 90%
formamide, 5 mg bromophenol blue). The resultant final samples
were analysed on a urea-PAGE gel[19] and bands were visualised
using a Typhoon 9410 phosphoimager (GE Healthcare, Figure 5).
DNA/LNA-gapmer 2 and a native DNA-ON with the same sequence
(5’-AGATCTCTCTCTAGATT-3’) were used as positive controls. Fur-
thermore, two negative controls were included: i) incubation under
the conditions described above, but lacking the gapmer strand, to
determine the influence of the activating strand; ii) incubation
under the conditions described above, but lacking both the gapmer
strand and RNase H, to elucidate potential unspecific RNase activity
of the RNase H preparation.
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